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Abstract 
Objectives: Measurement of serum free light chains (FLC) is critical in diagnosis, 
prognosis and monitoring treatment responses in AL amyloidosis.  The FreeliteTM 
assay (polyclonal antibodies to hidden light chain epitopes) the current gold 
standard.  We compare a new assay - a mixture of monoclonal antibodies to light 
chain epitopes (N latex).  Methods: 240 serum samples from 94 consecutively newly 
diagnosed AL amyloidosis patients (at least 3 serial serum samples during the first 6 
months) analysed at the National Amyloidosis Centre, London from January 2011 to 
April 2012. Concordance in detecting abnormal light chain components and 
haematologic response was assessed at 2, 4 and 6 months.  Results: Kappa and 
lambda clonal light chain involvement; 21% and 79% respectively, with an abnormal 
kappa/lambda ratio or detectable protein in 78.7%. Median kappa, lambda and 
difference in involved and uninvolved FLCs by FreeliteTM and N-Latex assays: 
17.3mg/L versus 16mg/L (R2=0.91), 48.8mg/L versus 52.6mg/L (R2=0.52) and 
43.2mg/L versus 39.1mg/L respectively. Discordant kappa/lambda ratios at 
presentation: 10/90 abnormal by FreeliteTM; normal by N Latex and 11/90 abnormal 
by N Latex; normal by FreeliteTM. Conclusions: Both FLC assays show good 
correlation in detecting the abnormal light chain subtype with discordance in absolute 
values, thus not interchangeable.  
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Introduction 
Systemic AL amyloidosis is a protein deposition disease in which the underlying  
clonal proliferation of plasma cells produce excess of unstable immunoglobulin light 
chains, with deposition of immunoglobulin light chains in tissues and organs leading 
to impairment of the latter.1, 2  Tracking and monitoring AL amyloidosis is a challenge 
as most patients have barely a detectable intact monoclonal immunoglobulin.  The 
discovery of serum free light chains as a measure in 2000, led to a development that 
revolutionised this rare disease.  The serum FreeliteTM assay measures 
immunoglobulin free light chains using polyclonal sheep antibodies directed against 
hidden epitopes on the light chain molecule giving an accurate measurement of 
serum free kappa and lambda.  Our group initially reported the utility of this assay in 
20023 in this disease, with many studies following.  This assay now forms a standard 
part of the baseline and serial follow up assessments in systemic AL amyloidosis4, 5, 
and is part of the revised Mayo staging system and standard international consensus 
criteria for disease response assessment.6-8 
Polyclonal antibodies to light chain epitopes in the FreeliteTM assay continue to be 
prepared from specifically immunised sheep.  However, in any naturally occurring 
antibody mixture, standardisation remains complex and inter-assay variability is a 
distinct possibility.  Efforts have been made to develop monoclonal antibodies to the 
hidden light chain epitopes that would recognise and replicate the success of the 
polyclonal assay and allow better inter-assay standardisation.  A group in the 
Netherlands working with Siemens, Germany, has developed this technology using a 
mixture to two kappa and two lambda monoclonal antibodies to the hidden epitopes 
of the constant region of the immunoglobulin light chain molecules.9  The references 
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ranges of both the new N-Latex assay and the polyclonal FreeliteTM assay are 
similar.  
With increasing adoption by laboratories of the novel assay, it is important to assess 
the utility of the new assay compared to the current reference FreeliteTM assay. We 
report a comparison of serum free light chains measured both immunoassays at 
diagnosis and three further time points in during the initial chemotherapy for patients 
with systemic AL amyloidosis.  
Materials and Methods 
This study was conducted at the National Amyloidosis Centre, London, UK (NAC).  
Consecutive patients with systemic AL amyloidosis seen at the NAC and under 
prospective follow up from January 2011 and April 2012 undergoing chemotherapy 
for AL amyloidosis were included, if they had a baseline serum sample at initial 
diagnosis and at least 3 of 4 blood samples available including from baseline 2, 4 
and 6 month follow up point intervals following treatment with chemotherapy.  As per 
standard clinical practice, all newly diagnosed systemic AL patients have monthly 
serum samples taken during the first year of diagnosis. Diagnosis of amyloidosis was 
confirmed in all cases with a tissue biopsy demonstrating characteristic birefringence 
on Congo red staining. Typing of AL amyloidosis was confirmed by 
immunohistochemical staining with appropriate antibodies and by exclusion of 
hereditary amyloidosis, where necessary, by genetic sequencing of the genes 
implicated. All patients underwent systematic review at presentation and detailed 
follow up assessments at 6 monthly intervals or as clinically indicated.  Assessment 
included clinical examination, detailed blood and urine analysis (including 
assessment of serum and urine monoclonal immunoglobulin and serum free light 
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chains at diagnosis and at 6 months), serial 123I labelled serum amyloid P component 
(SAP) scintigraphy to assess the whole body amyloid load, electrocardiogram (ECG) 
and an echocardiogram.  Organ involvement was defined according to the 
international amyloidosis consensus criteria.(18)  Mayo disease stage was defined 
as per the criteria published by Dispenzieri et al and Kumar et al.8,10  
Serum samples were separated and stored at -80ºC.  All retrieved samples were tested in 
duplicate for measurement with FreeliteTM (The Binding site Ltd, Birmingham, UK) and N-
Latex (Siemens Healthcare Diagnostics, Germany) according to the manufactures’ protocols 
on a BNTMII System nephelometer (Siemens, Germany). The precision of the assay 
(%CV) was confirmed at multiple light chain concentrations and also within-batch 
precision.  The CV was <5% when analysing a single sample multiple times at all 
concentrations.  The between batch CV (measuring a single sample in one run, then 
again in a second run, and again in a third run etc) was also <5% at all FLC 
concentrations except at low very concentrations of <2mg/L the CV is 12.5% for 
kappa; for lambda values within and between batch %CV is <10% at all levels. 
Samples are checked for prozone phenomenon by diluting samples where there is a 
suspicion of prozone using 1:2000 dilution compared to the standard 1:100 dilution. 
If the result of the 1:2000 dilution is more than 4x different to the 1:100 result then we  
state that prozone has been detected and amend the result accordingly. 
{Vercammen, 2011 #6261}. Immunofixation was done using the Sebia Hydrasys 
analyser using agarose gels (XXX companyXX).  Since this is a qualitative method, 
we run positive and negative controls but cannot assess the precision of it, nor do we 
do recovery experiments.  
Haematologic response was assessed on results of the free light chain (FLC) assays 
in available samples at 2 months; 90 FreeliteTM and 90 N Latex, 4 months; 91 
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FreeliteTM and 89 N Latex, 6 months; 61 FreeliteTM and 62 N Latex. Discrepancies in 
the number of available samples for analysis were secondary to inadequate quantity 
of serum or error readings in the analysed sample, hence excluded for analysis. In 
total, serum free light chains were measured in a total of 240 serum samples in 
duplicate using the FreeliteTM and N Latex assays.  
We performed a correlation analysis between the 2 FLC assays of results for kappa, 
lambda and kappa/lambda ratio, examining the qualitative comparison. 
Haematologic response was assessed as per the international amyloidosis 
consensus criteria,6,7 typically developed using results obtained from the FreeliteTM 
assay. This study was not powered to develop new response criteria for the N-latex 
assay. Statistical analysis was performed using SPSS software with a p value of less 
than 0.05 considered to be significant. We have stated median values with minimum 
and maximum ranges. We calculated the Pearson’s coefficient to evaluate the 
agreement and concordance between the two FLC assays, with use of scatter plots 
to illustrate this. Kaplan Meier curves were used to assess prognostic utility of both 
assays. 
Results 
A total of 94 patients were identified from the National Amyloidosis database over 
this period of time. The available samples at each time point included: at baseline; 
90 FreeliteTM and 90 N Latex, 2 months; 90 FreeliteTM and 90 N Latex, 4 months; 91 
FreeliteTM and 89 N Latex, 6 months; 61 FreeliteTM and 62 N Latex.  All patients had 
a baseline sample as per inclusion criteria.  The median age was 64 years (range 
55.2-72.2 years) at diagnosis and 48 (51%) male. Cardiac involvement was present 
in 43%; 23% with Mayo stage 3, renal involvement in 72 (76%), liver involvement in 
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10 (10%).  Of the patients in this group, 74 (78.7%) had either a monoclonal protein 
detectable in the serum, urine by immunofixation or had an abnormal free light chain 
ratio, with 20 (21.3%) having no abnormal free light chain ratio or M protein by urine 
or serum investigations.  50 (53.2%) of this group had a measurable monoclonal 
protein ≥ 1g/L.  The revised Mayo disease stage, which incorporates the dFLC, using 
FLC measured by FreeliteTM/N-Latex assays: Stage 1: 20.2%/25.5%, Stage II: 
47.9%/43.6%, Stage III: 29.8%/30.9%, and Stage IV 2.1%/0%, respectively. 
The FLC in baseline samples showed an abnormal kappa in 41% and lambda in 
63% by FreeliteTM assay, and abnormal kappa in 32% and 67% by N Latex assay.  
The kappa and lambda light chain was 17 (18%) and 75 (82%) respectively.  The 
FreeliteTM assay showed a median kappa of 17.3mg/L (range 0.3-1440), median 
lambda 48.8mg/L (range 7.5-1430) and median difference in involved and 
uninvolved light chains (dFLC) of 43.2 mg/L (range 55-247.9).  The median abnormal 
kappa was 34.75mg/L (range 0.3-1440) and abnormal lambda 93.85mg/L (range 27-
1430).  The N latex assay had corresponding concentrations: median kappa 16mg/L 
(range 2.35-770), median lambda 52.6mg/L (range 3.65-786) and median dFLC 39.1 
mg/L (range 58.3-247). The median abnormal kappa by the N-Latex assay was 28.1 
(range 2.35-770) and abnormal lambda 77.9 (3.7-786). There was not a significant 
difference in the absolute kappa and lambda values obtained by either assay (kappa 
median 34.8 vs. 28.1 p = 0.64; lambda median 93.85 vs. 77.9; p = 0.41). 
The concordance between the two assays was assessed by categorising the results 
into serum kappa, serum lambda and kappa: lambda ratio as abnormally high, 
normal and abnormally low as per the normal ranges by each manufacturer. The 
concordance for the serum kappa light chain was 85% with R2=0.91 and Pearson 
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correlation co-efficient r=0.804 (p = 0.0001).  The concordance for serum lambda 
was 75.5% with R2=0.52 and Pearson correlation coefficient r=0.50 (p=0.0001).  The 
concordance for the kappa/lambda ratio for the respective values 78.8%, R2=0.87 
and r=0.97 (p=0.0001) (Fig 1A, 1B and 1C respectively and Table 1). 
There were discordant kappa/lambda ratios at presentation with 10/90 abnormal by 
FreeliteTM but normal by N Latex assay, and 11/90 abnormal by N Latex and normal 
by FreeliteTM (Table 2). There were 10 patients with an abnormal ĸ/Ɩ ratio by 
FreeliteTM assay (normal by N Latex assay): positive IFE by both urine and serum 
(n=4), positive IFE only by serum (n=2) and positive IFE only by urine (n=3), 
negative IFE by urine and serum (n=1). There were 11 patients with an abnormal ĸ/Ɩ 
ratio by N Latex assay (normal by FreeliteTM assay): positive IFE by both urine and 
serum (n=3), positive IFE by only serum (n=3), positive IFE by only serum (n=4) and 
negative IFE by urine and serum (n=1). 
The diagnostic sensitivity (true positive) and specificity (true negative) with 
agreement of the ĸ/Ɩ ratios of the FreeliteTM and N Latex assays were calculated 
(Table 3 and Table 4). 
We evaluated the clinical impact of these differences in assessing haematologic 
response according to the revised Consensus criteria7 of those with measurable 
dFLC at 2, 4 and 6 months post chemotherapy treatment for patients with sampels 
available at each of these time points. At baseline 54 (60%) and 51 (56.7%) had a 
dFLC >50 mg/L (the minimum defined to assess the free light chain response). Using 
FreeliteTM and N Latex assays respectively, at 2 months, a complete response (CR) 
was achieved in 23% and 32%, partial response (PR) in 17% and 14% and no 
response (NR) in 57% and 49% of the evaluable patients.  There was a discrepancy 
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in the proportion classed responders at each time point as depicted in fig 2A and 2B.  
At 2 months, an abnormal kappa/lambda ratio was present in 45.6% by FreeliteTM 
and 46.7% by N Latex assays. Monitoring of the kappa/lambda ratio by both assays 
produced similar results, although there were subtle differences at 4 months; with 
34.4% and 38.2% and 6 month; 30% and 36.1% by FreeliteTM and N Latex assays 
respectively (figure 2).  
The estimated overall survival (OS) of the 94 patients was 24.1 months with a 
median follow-up of 8.6 months. All patients were treated with chemotherapy 
regimens including: Cyclophosphamide/Thalidomide/Dexamethasone (CTD), n=36, 
Bortezomib/(Cyclophosphamide)/Dexamethasone (VCD), n=21, 
Revlimid/Dexamethasone, n=4, Melphalan/Prednisolone/(Thalidomide) (MPT), n=5, 
Rituximab based regimens n=4, CTD followed by CVD, n=21, MP followed by VD 
n=3. Given the differences in the proportion of patients achieving a partial response 
(PR) by both assays at 4 months, we evaluated the OS of those achieving a partial 
response or greater by both assays.  There was a significant improvement in the OS 
for patients achieving a partial response or better at 4 months by each assay, with 
the median OS not reached in either case.  The survival benefit for those achieving a 
PR or better by FreeliteTM at 4 months was HR 7.84, 95% CI (0.94-65.57), log rank p 
= 0.03 and by the N-Latex assay HR 95.47, 95% CI (0.11-79601), log rank p = 
0.004. 
Discussion 
We report here the comparative utility of using two different assays (one using 
polyclonal anti-light chain antibodies and other using a combination of monoclonal 
anti-light chain antibodies) for detection of and serial monitoring of serum free light 
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chains in patients with systemic AL amyloidosis undergoing chemotherapy.  This 
study finds that the two assays are broadly comparable for detection of abnormal 
light chains in the serum with a greater concordance for detection of kappa than for 
lambda immunoglobulin free light chain.  However, discrepancies were also present 
with the numbers abnormal, the absolute light chain value and time point to reach 
thresholds for haematological responses different in some which may also impact on 
survival. 
The FreeliteTM assay was the only assay available for measurement of serum free 
light chains until the development of the N-Latex assay, allowing a different method 
to study these complex molecules; but standardisation is needed between the two 
assays.  Both assays have been studied in myeloma as well as normal controls to 
assess imprecision, underestimation; antigen excess or non-linear reactivity and 
overestimation; polymeric forms reacting at multiple antigenic FLC sites of results.11-
13  However, it is important to emphasise that the free light chain component in 
Myeloma is higher than in patients with AL amyloidosis, and as such direct 
extrapolation of the results from our study cannot be translated with regard to 
Myeloma patients. Our study was not focused on the biochemical or technical 
aspects of either assay, but was designed to assess the clinical utility of each assay 
in a routine clinical setting in systemic where the serum free light chains are typically 
abnormal, but low and where FLC measurements form the cornerstone of patient 
assessment and monitoring.  In previous studies in patients with a monoclonal 
gammopathy, the kappa showed the best correlation between both FLC assays, 
followed by kappa/lambda ratios and then lambda, with the Pearson coefficients 
0.97, 0.83 and 0.91 respectively,14 and other studies have also shown comparable 
results.15, 16 Pretorius et al compared the utility of both FreeliteTM and N Latex assays 
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in 116 samples showing large variations between both assays, precluding the 
interchange of results, with statistically significant non-linearity occurring in 
approximately half of the monoclonal and polyclonal samples (kappa and lambda) for 
both assays.17 
The current study confirms that in systemic AL amyloidosis, there is, in general, 
excellent concordance between both the assays in detecting an excess of serum 
free light chains with better concordance of kappa than lambda as previously 
reported. The overall concordance in our study for kappa, lambda and kappa/lambda 
ratios were 85.5%, 75.5% and 78.8% respectively - similar to another study 70-80% 
14 but lower than another study quoting the concordance as approximately 90%.9  
The diagnostic sensitivity with respect to the serum and urine IFE results was lower 
than expected in both assays, 54.3% and 56.7% by FreeliteTM and N Latex assays 
respectively. Some patients had lower serum free light chain values at diagnosis, 
with the presence of serum and/or urine IFE, clinical symptoms and diagnostic 
biopsy needed to prove the diagnosis. The serum free light chain level is often lower 
than in Myeloma patients. Approximately 10% of cases with each assay detected an 
abnormal FLC ratio that was not detected by the other assay. The underlying reason 
for this discordance is difficult to fully explain, given the details of antibodies used to 
detect the free light chains in both assays are commercially confidential.  Due to the 
nature of the monoclonal disease underlying AL amyloidosis, the mutational 
signature of the plasma cell DNA in each AL light chain is unique and each light 
chain sequence is unique in every AL patient.  That is most likely explanation leading 
to the anti-light chains antibodies in each assay do not recognising the epitopes on 
the respective light chains and hence there is a false negative signal.  The Mayo 
clinic group, using mass spectrometry, has recently demonstrated that such samples 
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also contain a monoclonal light chain. This suggests that currently neither method is 
perfect for detection of all abnormal monoclonal free light chains but as different 
patients “detected” or “missed” by either assay, there may be a role for repeating the 
FLC measurement by the other assay if an abnormality is not detected in a patient 
with one assay.  This may help to, at least partly, overcome the problem in AL 
amyloidosis of lack of evaluable light chains in a certain proportion of all patients.3  
We compared the ĸ/Ɩ ratios and the IFE results showing that both assays had similar 
sensitivities (54.3 and 56.7%) and specificities (86.2 and 86.8%) for the FreeliteTM 
and N Latex assays respectively.  
This is the first study to examine serial parallel samples to assess the serum free 
light chain responses by both assays simultaneously. Although there is broad 
agreement in the response assessment as a percentage of total patients with both 
assays, there were important differences in the proportion of patients who reach the 
current threshold used to define a partial or very good partial response.  Eighteen 
patients reached a PR and VGPR earlier by N-Latex assay than the same class of 
response by the FreeliteTM assay. This is likely as the assays have very different 
antibodies which measure the free light chain in serum and hence the actual slopes 
of the standard curves are not same.  The response criteria in AL amyloidosis have 
been derived using ROC analysis based on survival of patients using various light 
chain thresholds obtained by the FreeliteTM assay.  Thus the current thresholds are 
clinical and not biochemical end points.  The N-Latex assay classified patients as 
responders at an earlier time point than the FreeliteTM assay, hence designing a 
study to examine a clinically relevant threshold for defining a response with N-latex is 
important.  Mollee et al described a comparison of these 2 assays in 62 patients with 
32 samples post treatment also showing variations in the dFLC response and hence 
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haematologic response. The median reduction in dFLC was 68% for the N-Latex 
assay and 77% for the Freelite™ assay (p=0.04), with a partial response assigned 
by both assays predicting overall survival (N-Latex p=0.0015, Freelite™ p=0.022). 
{Mollee, 2013 #6262} 
Achieving a haematologic response translates into a survival benefit.  However, the 
earlier classification of a greater proportion of patients as responders by the N-Latex 
assay has risks, with the treatment duration in amyloidosis often shorter than in 
myeloma, with a lower threshold to stop treatment earlier in the responders given the 
toxicity and tolerance to the treatments.  Unless thresholds are redefined, patients 
classed as responders by the N-Latex assay may get undertreated and hence carry 
a risk of shorter time to disease progression.   
This current study needs to be interpreted in the context of certain limitations.  The 
numbers are small and all patients did not have serial samples available.  Although 
the patients recruited in this study are serial AL patients seen at the NAC, there is a 
selection bias as all patient were required to have serial samples for six months i.e. 
only six month survivors are recruited thereby excluding a substantial number of 
patients with stage III cardiac AL amyloidosis where there is still 30-40% mortality in 
the first six months.18  A study of truly unselected serial patients is needed to assess 
the true utility of these assays.  There was higher than expected proportion of 
patients with non-evaluable light chains, likely due to selection of the survivors who 
are typically patients with early stage disease and lower serum free light chain 
burden.   
In conclusion, both FreeliteTM and N Latex assays are important in detecting the 
abnormal FLC in patients with systemic light chain amyloidosis. Our study 
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demonstrated excellent correlation between the assays for detecting the abnormal 
light chain subtype, with discordance in the absolute values of the FLC suggesting 
that cross assay interpolation is impossible.  Furthermore, each assay appears to 
have limitations, in missing random yet different patients suggesting a need by both 
manufacturers to further optimize the anti-light chain antibodies underpinning the 
respective assays.  Studies using clinical end points are needed to harmonize the 
response assessment criteria for each assay; given the values may not be 
equivalent and validation of the new assay is important in clinical and trial results if 
this emerges as a more widely used assay in diagnosing and monitoring systemic AL 
patients. Designing future clinical trials in AL amyloidosis incorporating FLC 
measurement by both assays would make a substantial contribution to our 
understanding and harmonisation of the field.  
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Table 1 Concordance analysis for kappa (A), lambda (B) and kappa/lambda 
ratio (C) for the 2 FLC assays. 
Group Number  N Latex FLC 
(mg/L) 
FreeliteTM FLC 
(mg/L) 
Pearson’s  
correlation 
FLC ĸ 90 16.1 (2.35-770) 17.3 (0.3-1440) 0.804 
FLC Ɩ 90 52.6 (3.65-786) 48.8 (7.5-1430) 0.493 
ĸ/Ɩ ratio 90 0.68 (0.01-63.56) 0.88 (0.0002-224.7) 0.97 
FLC – Free light chain; mg/L – milligrams per litre; ĸ – kappa; Ɩ – lambda 
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Table 2. Kappa/Lambda ratios at presentation 
 N Latex Ratio 
Normal Abnormal Total 
FreeliteTM 
Ratio 
Normal 27 11 38 
Abnormal 10 42 52 
Total 37 53 90 
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Table 3. Clinical sensitivity and specificity of the FreeliteTM assay and immunofixation 
electrophoresis (IFE). 
                                                         IFE (serum and urine) 
FreeliteTM 
ĸ/Ɩ ratio 
Positive Negative Total 
Abnormal 44 7 51 
Normal 37 2 39 
Total 81 9 90 
 
Sensitivity 54.3%, Specificity 86.2% 
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Table 4. Clinical sensitivity and specificity of the FreeliteTM assay and immunofixation 
electrophoresis (IFE). 
                                                         IFE (serum and urine) 
N Latex 
ĸ/Ɩ ratio 
Positive Negative Total 
Abnormal 46 7 53 
Normal 35 2 37 
Total 81 9 90 
Sensitivity 56.7%, Specificity 86.8% 
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Figure 1. Scatter plots of  N Latex and FreeliteTM free light chain assays for (A) 
kappa N Latex (n=91) and FreeliteTM (n=91) and (B) lambda N latex (n=90) and 
FreeliteTM (n=90) and (C) kappa/lambda ratio (n=90) illustrating the concordance of 
both free light chain assays. 
 
Figure 2A and B. Difference in involved and uninvolved free light chain (dFLC) 
response in patients with evaluable disease. (A) Percentage of evaluable patients 
assessed at 2, 4 and 6 months according to haematologic response including no 
response (NR), partial response (PR), very good partial response (VGPR) and 
complete response (CR) with (B) illustrated the differences of the abnormal 
kappa/lambda ratio at set intervals between the FreeliteTM and N Latex assay. There 
was no statistical difference between the 2 assays by chi-square test, illustrated in 
both figures with corresponding p values. 
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